Curis Inc (CRIS) is a publicly traded Healthcare sector company. As of May 21, 2026, CRIS trades at $0.50 with a market cap of $18.71M and a P/E ratio of -0.62. CRIS moved +4.22% today. Year to date, CRIS is -49.71%; over the trailing twelve months it is -76.64%. Its 52-week range spans $0.46 to $5.54. Analyst consensus is strong buy with an average price target of $11.00. Rallies surfaces CRIS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Curis Reports $24.2M Q1 Loss, Secures $80.8M PIPE Financing: Curis posted a Q1 net loss of $24.2 million on zero revenues versus a $10.6 million loss in Q1 2025, as R&D spending fell to $6.4 million. The company secured $80.8 million in PIPE financing, ended March with $15.0 million cash and advances emavusertib trials in PCNSL and CLL.
| Metric | Value |
|---|---|
| Price | $0.50 |
| Market Cap | $18.71M |
| P/E Ratio | -0.62 |
| EPS | $-0.81 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.54 |
| 52-Week Low | $0.46 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $7.06M |
| Net Income | $-21.16M |
| Gross Margin | 0.00% |
3 analysts cover CRIS: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $11.00.